Modulation of GLP-1 levels by a genetic variant that regulates the cardiovascular effects of intensive glycemic control in ACCORD

Diabetes Care

Volumn 41, Issue 2, 2018, Pages 348-355

  Shah, Hetal S ^a,b   Morieri, Mario Luca ^a,b   Marcovina, Santica M ^c   Sigal, Ronald J ^d   Gerstein, Hertzel C ^e   Wagner, Michael J ^f   Motsinger Reif, Alison A ^g   Buse, John B ^h   Kraft, Peter ⁱ   Mychaleckyj, Josyf C ^j   Doria, Alessandro ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f University of North Carolina   (United States)

^g NORTH CAROLINA STATE UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; EXENDIN 4; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 5; LEPTIN RECEPTOR; SODIUM GLUCOSE COTRANSPORTER 1;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC RISK; GENETIC RISK SCORE; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GLYCEMIC CONTROL; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUANTITATIVE TRAIT LOCUS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETIC ANGIOPATHY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 85041213368     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1638     Document Type: Article

References (28)

1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium, International Diabetes Federation, 2015
2. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545–2559
3. Shah HS, Gao H, Morieri ML, et al. Genetic predictors of cardiovascular mortality during intensive glycemic control in type 2 diabetes: findings from the ACCORD clinical trial. Diabetes Care 2016;39:1915–1924
4. Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Goff DC Jr. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res Clin Pract 2012;95:389–398
5. Sandoval DA, D’Alessio DA. Physiology of pro-glucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95:513–548
6. Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes 2006;55(Suppl. 2):S70–S7
7. Müssig K, Staiger H, Machicao F, Häring H-U, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010; 53:2289–2297
8. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153–165
9. Ravassa S, Zudaire A, Díez J. GLP-1 and cardio-protection: from bench to bedside. Cardiovasc Res 2012;94:316–323
10. Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet 2011;88:586–598
11. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003;52:252–259
12. Preiss D, Dawed A, Welsh P, et al.; DIRECT Consortium Group. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes Metab 2017;19:356–363
13. Zietek T, Rath E. Inflammation meets metabolic disease: gut feeling mediated by GLP-1. Front Immunol 2016;7:154
14. Shiraki A, Oyama J, Komoda H, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-a-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012;221: 375–382
15. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 2014;9:e97554
16. Lee YS, Park MS, Choung JS, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 2012;55: 2456–2468
17. Marso SP, Daniels GH, Brown-Frandsen K, etal.;LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 311–322
18. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Am Heart J 2013;166:823–830.e5
19. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844
20. MacLusky NJ, Cook S, Scrocchi L, et al. Neuro-endocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000;141:752–762
21. Ghosal S, Packard AEB, Mahbod P, et al. Disruption of glucagon-like peptide 1 signaling in Sim1 neurons reduces physiological and behavioral reactivity to acute and chronic stress. J Neurosci 2017;37:184–193
22. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 1999;277:R582–R590
23. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694–699
24. Liu Q, Anderson C, Broyde A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010;9:76
25. van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab 2013;15:593–606
26. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242–2252
27. Nathanson D, Zethelius B, Berne C, et al. Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Di-abet Med 2011;28:301–305
28. Nathanson D, Zethelius B, Berne C, Holst JJ, Sjöholm A, Nyström T. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. Diabetologia 2010;53: 277–280